United Kingdom Transfection Reagents and Equipment Market Insight
The United Kingdom Transfection Reagents and Equipment Market is growing at an 9.14% CAGR, driven by rising gene therapy research, expanding biologics development, and increasing academic funding, with innovations in lipid-based reagents, electroporation systems, and advanced cell engineering technologies improving efficiency and outcomes.
United Kingdom Transfection Reagents and Equipment Market Insights Forecasts to 2035
- The United Kingdom Transfection Reagents and Equipment Market Size Was Estimated at USD 77.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 9.14% from 2025 to 2035
- The United Kingdom Transfection Reagents and Equipment Market Size is Expected to Reach USD 185.6 Million by 2035
Notable Insights for United Kingdom Transfection Reagents and Equipment Market
- By product type, transfection reagents dominated, accounting for approximately 60–65% share in 2024, driven by widespread use in gene expression and silencing studies.
- By method, lipid-mediated transfection held approximately 50–55% share due to high efficiency and low cytotoxicity in mammalian cells.
- Approximately 250,000–300,000 transfection-based experiments are conducted annually across UK academic and biopharma laboratories, reflecting strong research activity.
- Around 65–75% of gene therapy and cell-based research projects utilize advanced transfection technologies, including electroporation and viral-free delivery systems.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Transfection Reagents and Equipment Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Transfection Reagents and Equipment Market
- Thermo Fisher Scientific
- Merck KGaA (MilliporeSigma)
- Lonza Group
- Bio-Rad Laboratories
- Promega Corporation
- Qiagen
- Agilent Technologies
- Polyplus-transfection SA
- Others
Recent Developments:
- In July 2025: Cellular Origins and the Cell and Gene Therapy Catapult partnered under an Innovate UK grant to advance automated cell therapy manufacturing using the Constellation platform.
- In August 2023: Mirus Bio launched RevIT AAV Enhancer, improving viral vector yields and reducing plasmid DNA usage, supporting efficient gene therapy production workflows using advanced transfection technologies.
Market Segmentation:
United Kingdom Transfection Reagents and Equipment Market, By Product Type
- Reagents
- Equipment
United Kingdom Transfection Reagents and Equipment Market, By Method
- Lipid-mediated Transfection
- Electroporation
- Calcium Phosphate Transfection
- Viral Transduction
- Others
United Kingdom Transfection Reagents and Equipment Market, By End User
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
United Kingdom Transfection Reagents and Equipment Market, By Distribution Channel
- Direct Sales
- Distributors
- Online Channels
Expert Views:
The UK Transfection Reagents and Equipment Market is expected to witness steady growth, driven by expanding gene therapy pipelines, increasing CRISPR-based research, and strong academic-industry collaboration. Experts emphasize that lipid-based reagents and electroporation technologies will remain dominant due to their efficiency and scalability. Government funding for life sciences and innovation in non-viral delivery systems are accelerating adoption. Additionally, the growing demand for personalized medicine and advanced biologics is expected to further boost transfection technology usage, shaping market expansion through 2035.